HOME >> BIOLOGY >> NEWS
Actonel significantly reduced moderate and severe vertebral fractures

San Antonio, TX (September 20, 2002) A new analysis of scientific data presented at today's meeting of the American Society for Bone and Mineral Research (ASBMR) showed that a 5 mg dose of Actonel (risedronate sodium tablets) daily significantly reduced moderate and severe vertebral fracture risk by 70 percent within one year in postmenopausal women with osteoporosis. Furthermore, the significant effect on vertebral fracture risk was sustained over three years.

This analysis combined data from two large Actonel clinical trials, VERT-NA and VERT-MN, which included postmenopausal women with either one prevalent vertebral fracture and low bone mineral density (BMD), or with at least two prevalent vertebral fractures. The objective of this analysis was to compare the incidence of moderate or severe vertebral fracture at one year in women who received Actonel or placebo. Fracture severity was determined using the fracture severity scoring system developed by Harry Genant, M.D., Professor of Radiology, Medicine, Epidemiology and Orthopaedic Surgery at the University of California, San Francisco, an investigator and pioneer of the assessment method used in the analysis.

Recent studies show severity of prevalent vertebral fractures is a predictor of future vertebral and non-vertebral fracture risk; patients with more severe baseline vertebral fractures are more likely to experience subsequent vertebral and non-vertebral fractures. Therefore, reducing the incidence of moderate or severe vertebral fractures may help decrease the risk of future fractures.

"The ultimate goal of osteoporosis treatment is to prevent fractures," said Dr. Genant, "These new findings, combined with previous Actonel clinical data showing reductions in both risk of first vertebral fracture and multiple vertebral fractures, suggest that Actonel reduces fracture risk across a range of osteoporotic severity."

According to
'"/>


20-Sep-2002


Page: 1 2 3 4

Related biology news :

1. Rare mutations can significantly increase risk factor for heart disease
2. Cancer health risk significantly underestimated by EPAs ambient model estimates
3. Double mastectomies significantly lower risk of breast cancer in women who are genetically at risk
4. HAART therapy significantly prolongs survival in AIDS patients with central nervous system lymphoma
5. ENBREL rapidly, significantly improved back pain, mobility, function in ankylosing spondylitis
6. Once weekly ENBREL significantly reduced rheumatoid arthritis pain, inflammation & improved function
7. Cognitive abilities increase significantly with time in most prematurely born children
8. Combining key ingredients of vegetarian diet cuts cholesterol significantly, says study
9. Pollen productionand allergiesmay rise significantly over next 50 years
10. Brain size in premature infants significantly smaller than full-term babies
11. Multicenter study shows Benecol spread significantly reduces cholesterol levels in patients taking statin drugs

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/30/2016)... 2016 Not many of us realize that we spend ? of our ... need to do it well. Inadequate sleep levels have been found to lead to ... and even cancer. Maybe now is the best time to rethink how ... to manage their sleep quality? Continue Reading ... ...
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s high-speed AFIS    ... ... DERMALOG is Germany's largest Multi-Biometric supplier: The ... Identification Systems) ... Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification System is part of ...
(Date:11/22/2016)... 22, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... and Life Sciences Awards as "Most Outstanding in ... unprecedented year of recognition and growth for MedNet, which ... years. iMedNet ™ , MedNet,s ...
Breaking Biology News(10 mins):
(Date:11/30/2016)... New York , November 30, 2016 ... consolidated as a few players hold a dominant share ... Group, Charles River Laboratories International, Inc., and Merck KGaA, ... market in 2015. Transparency Market Research observes that these ... are focused on development products that are do not ...
(Date:11/30/2016)... 30, 2016  Tempus, a technology company focused ... Penn,s Abramson Cancer Center have partnered to better ... to immunotherapy treatment based on next generation genomic ... of a research collaboration, Tempus will provide sequencing ... patient data to Penn. Utilizing next-generation sequencing, machine ...
(Date:11/30/2016)... (PRWEB) , ... November 30, 2016 , ... SSCI, the ... to discuss the implications of the latest FDA guidance on pharmaceutical cocrystals as ... 2016 in Cambridge, MA. , The event follows the successful November 15th ...
(Date:11/30/2016)... (PRWEB) , ... November 30, 2016 , ... ... discovery and development of precision treatments for neurodegenerative diseases, today announced that all ... (announced on November 3, 2016) blocked propagation of toxic, prion-like forms of Amyloid ...
Breaking Biology Technology:
Cached News: